News
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
US FDA clears Lomond Therapeutics’ IND application for phase 1 multicenter study of lonitoclax in patients with relapsed/refractory AML: Dover, Delaware Monday, June 23, 2025, 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback